41-year-old woman with invasive ductal carcinoma (G2, luminal B) of right breast

41-year-old woman with invasive ductal carcinoma (G2, luminal B) of right breast. A, CC (left) and MLO (right) low-energy images from pre-NAT CEM performed on 25th day of luteal phase show a 60-mm architectural distortion (line on CC) in the central portion of the right breast. B, CC (left) and MLO (right) recombined images from pre-NAT CEM show marked background parenchymal enhancement, hindering lesion evaluation; 90-mm non-mass regional enhancement (line) was described. C, Axial fat-saturated T1-weighted unenhanced MR image shows a 70-mm hypointense irregular mass (line) with not circumscribed margins in the central portion of right breast. D, Axial fat-saturated T1-weighted post-contrast MR images shows corresponding fast initial enhancement (line) with delayed plateau.


June 22, 2022 — According to ARRS’ American Journal of Roentgenology (AJR)contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

“After NAT for breast cancer, CEM and MRI yielded comparable assessments of lesion size (both slightly overestimated vs pathology) and RECIST categories, and no significant difference in specificity for pathologic complete response,” wrote corresponding author Rubina Manuela Trimboli of IRCCS Humanitas Research Hospital in Milan, Italy. Noting that MRI had higher sensitivity for pathologic complete response, “delayed CEM acquisition may help detect residual ductal carcinoma in situ (DCIS).”

Trimboli and team’s prospective study included 51 patients (mean age, 46 years) with biopsy-proven breast cancer from May 2015 to April 2018, who were candidates for NAT. Patients underwent both CEM and MRI before, during, and after NAT: pre-NAT, mid-NAT, and post-NAT, respectively. Post-NAT CEM included a 6-minute delayed acquisition. One breast radiologist with experience in CEM reviewed CEM examinations; one breast radiologist with experience in MRI reviewed MRI examinations.

Compared with pathology, post-NAT CEM, MRI, and delayed CEM systematically overestimated residual tumor size by 0.8 mm, 1.9 mm, and 1.2 mm, respectively. For detecting pathologic complete response by post-NAT imaging, sensitivity and specificity were 81% and 83% for CEM, 100% and 86% for MRI, and 81% and 89% for delayed CEM.

“While MRI remains the preferred test for NAT monitoring,” the authors of this AJR article concluded, “the findings support CEM as a useful alternative when MRI is contraindicated or not tolerated.”

For more information: www.arrs.org

Related Digital Breast Imaging Content:

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings

AI DBT Impact on Mammography Post-breast Therapy

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography

Related Breast MRI content:

Contrast-Enhanced In-Phase Dixon Sequence: Impact on Biopsy Clip Detection on Breast MRI

Breast MRI Illuminates Risk of Second Breast Cancer

Contrast-Enhanced Mammography vs. MRI: Neoadjuvant Therapy Response in Breast Cancer

Breast MRI Shows IUDs Have Systemic Effects

VIDEO: Use of Breast MRI Screening in Women With Dense Breasts — Interview with Christiane Kuhl, M.D.

Abbreviated MRI Outperforms 3-D Mammograms at Finding Cancer in Dense Breasts

VIDEO: Explaining Dense Breasts — Interview with Christiane Kuhl, M.D.

VIDEO: Use of Breast MRI Improved Cancer Detection in Dense Breasts in Dutch Study — Interview with Gillian Newstead, M.D.

Technologies to Watch in Breast Imaging

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

Rapid Breast MRI Screening Improves Cancer Detection in Dense Breasts

Breast MRI in Cancer Diagnosis


Related Content

News | Breast Imaging

October 2, 2023 — Digital radiography company Swissray has announced a strategic partnership with Koning Corporation ...

Time October 02, 2023
arrow
News | Radiation Oncology

October 2, 2023 — Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood ...

Time October 02, 2023
arrow
News | Women's Health

October 1, 2023 — In a first-of-its-kind study, people with breast cancer who underwent implant-based breast ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical ...

Time October 01, 2023
arrow
News | Women's Health

September 29, 2023 — Hologic, Inc., a global leader in women’s health, announced a series of activities promoting the ...

Time September 29, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
News | Mammography

September 26, 2023 — Artificial intelligence(AI) and machine learning tools have received a lot of attention recently ...

Time September 26, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
News | Mammography

September 22, 2023 — Hologic Inc. and Bayer announced an international partnership to deliver contrast-enhanced ...

Time September 22, 2023
arrow
News | Digital Pathology

September 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time September 22, 2023
arrow
Subscribe Now